Sanofi (SNY) Asset Writedowns and Impairment (2009 - 2010)
Sanofi's (SNY) quarterly Asset Writedowns and Impairment came in at -$588.0 million in Q4 2010, down 7.04% year-over-year from -$632.5 million in Q4 2009, and down 7.04% quarter-over-quarter from -$549.3 million in Q4 2009.
Powered by 
Analysis
Sanofi (SNY) Asset Writedowns and Impairment (2009 - 2010) Analysis & Trends
Sanofi has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting -$588.0 million for Q4 2010.
- In Q4 2010, Asset Writedowns and Impairment fell 7.04% year-over-year to -$588.0 million; the TTM figure through Dec 2010 stood at -$877.6 million (changed N/A YoY), while the FY2010 annual figure was -$574.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at -$588.0 million for Q4 2010 at Sanofi, down from -$549.3 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of -$549.3 million in Q4 2009 to a low of -$588.0 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |